Author

G. Beaudoin-Bussieres

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 13 Immunology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 17 Research Focus:host-pathogen & immune response· 16 Organism:human· 13 Assay:proteomics· 12 Research Focus:cell type annotation· 6 Research Focus:differential expression· 4 Research Focus:drug response / drug discovery· 4 Organism:mouse· 4

Frequent Co-Authors

A. Finzi· 19 shared J. Richard· 13 shared J. Prevost· 12 shared R. Gasser· 11 shared S. Ding· 10 shared A. Laumaea· 9 shared G. Goyette· 9 shared H. Medjahed· 9 shared

Activity by Year

2020-2023 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

19 shared papersMicrobiology

A. Finzi

Mutual co-authors in cluster

Author profile →

20 papers

Recent·Most cited

Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers

C. I. Stoddard, K. Sung, Z. A. Yaffe, H. Weight, G. Beaudoin-Bussieres, J. G. Galloway, S. Gantt, J. Adhiambo, E. R. Begnel, E. Ojee, J. Slyker, D. Wamalwa, J. Kinuthia, A. Finzi, F. A. Matsen, , J. Overbaugh

The paper compares SARS-CoV-2 antibody responses between infants and mothers, finding higher binding and functional antibody levels in infants, particularly in the fusion peptide region.

bioRxiv · Feb 6, 2023Immunology

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

Y. Chen, J. Prevost, I. Ullah, H. Romero, V. Lisi, W. D. Tolbert, J. R. Grover, S. Ding, S. Y. Gong, G. Beaudoin-Bussieres, R. Gasser, M. Benlarbi, D. Vezina, S. P. Anand, D. Chatterjee, , A. Finzi

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

bioRxiv · Jul 27, 2022 · PreprintMicrobiology

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

A. Laumaea, L. Marchitto, G. Beaudoin-Bussieres, S. Ding, R. Gasser, D. Chatterjee, G. Gendron-Lepage, H. Medjahed, H.-C. Chen, A. B. Smith, H. Ding, J. C. Kappes, B. H. Hahn, F. Kirchhoff, J. Richard, , A. Finzi

The paper shows that small CD4 mimetics expose ADCC epitopes on HIV-1-infected macrophages, making them susceptible to antibody-dependent cellular cytotoxicity.

bioRxiv · Jun 30, 2022Microbiology

An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys

L. Garnett, K. Tran, M. Chan, K. Tierney, Z. Schiffman, J. Audet, J. Lew, C. Meilleur, M. Chan, K. Manguiat, N. Tailor, R. Vendramelli, Y. Deschambault, G. Beaudoin-Bussieres, C. Bourassa, , D. Falzarano

COVAC-1, an S1 subunit vaccine with adjuvant, protects African green monkeys from SARS-CoV-2 challenge by reducing viral load and pathology in the respiratory tract.

bioRxiv · Jun 16, 2022 · PreprintMicrobiology

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice

I. Ullah, G. Beaudoin-Bussieres, K. Symmes, M. Cloutier, E. Ducas, A. Tauzin, A. Laumaea, P. Begin, W. Mothes, R. Bazin, A. Finzi, P. D. Uchil

This study shows that CCPs with high Fc-effector activity, rather than just neutralizing ability, are more effective in treating SARS-CoV-2 in mice.

bioRxiv · Jun 10, 2022Immunology

SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity

G. Beaudoin-Bussieres, A. Arduini, C. Bourassa, H. Medjahed, G. Gendron-Lepage, J. Richard, Q. Pan, Z. Wang, C. Liang, A. Finzi

This study shows that SARS-CoV-2 accessory protein ORF8 reduces antibody-dependent cellular cytotoxicity by binding CD16a and decreasing CD16 surface levels on monocytes and NK cells.

bioRxiv · Mar 30, 2022Immunology

Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron

M. Benlarbi, G. Laroche, C. Fink, K. Fu, R. P. Mulloy, A. Phan, A. Ariana, C. M. Stewart, J. Prevost, G. Beaudoin-Bussieres, R. Daniel, Y. Bo, J. Yockell-Lelievre, W. L. Stanford, P. M. Giguere, , M. Cote

This study identifies a MMP2/9-dependent entry pathway for SARS-CoV-2 and variants, showing differential usage and reduced activity in Omicron.

bioRxiv · Feb 19, 2022Microbiology

VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry

S. Ding, S. Y. Gong, J. Grover, M. Mohammadjavad, Y. Chen, D. Vezina, G. Beaudoin-Bussieres, V. T. Verma, G. Goyette, J. Richard, D. Yang, A. B. Smith, M. Pazgier, M. Cote, C. Abrams, , C. Baron

VE607 inhibits SARS-CoV-2 infection by stabilizing the RBD in the 'up' conformation and blocking S-ACE2 interaction across multiple variants.

bioRxiv · Feb 3, 2022Microbiology

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

D. Chatterjee, A. Tauzin, L. Marchitto, S. Y. Gong, M. Boutin, C. Bourassa, G. Beaudoin-Bussieres, Y. Bo, S. Ding, A. Laumaea, D. Vezina, J. Perreault, L. Gokool, C. Morrisseau, P. Arlotto, , A. Finzi

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

bioRxiv · Dec 21, 2021Microbiology

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

M. Nayrac, M. Dube, G. Sannier, A. Nicolas, L. Marchitto, O. Tastet, A. Tauzin, N. Brassard, G. Beaudoin-Bussieres, D. Vezina, S. Y. Gong, M. Benlarbi, R. Gasser, A. Laumaea, C. Bourassa, , D. E. Kaufmann

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

bioRxiv · Dec 18, 2021Immunology

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

Y. Chen, L. Sun, I. Ullah, G. Beaudoin-Bussieres, S. P. Anand, A. P. Hederman, W. D. Tolbert, R. Sherburn, D. N. Nguyen, L. Marchitto, S. Ding, D. Wu, Y. Luo, S. Gottumukkala, S. Moran, , M. Pazgier

The paper develops ACE2-Fc molecules that neutralize SARS-CoV-2 and show Fc-effector activity, effectively treating lethal infection in mice.

bioRxiv · Nov 24, 2021Microbiology

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

G. Beaudoin-Bussieres, Y. Chen, I. Ullah, J. Prevost, W. D. Tolbert, K. Symmes, S. Ding, M. Benlarbi, S. Y. Gong, A. Tauzin, R. Gasser, D. Chatterjee, D. Vezina, G. Goyette, J. Richard, , A. Finzi

bioRxiv · Sep 8, 2021 · PreprintMicrobiology

Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

I. Ullah, J. Prevost, M. S. Ladinsky, H. Stone, M. Lu, S. P. Anand, G. Beaudoin-Bussieres, K. Symmes, M. Benlarbi, S. Ding, R. Gasser, C. Fink, Y. Chen, A. Tauzin, G. Goyette, , P. D. Uchil

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

bioRxiv · Mar 22, 2021Immunology

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

A. Tauzin, M. Nayrac, M. Benlarbi, S. Y. Gong, R. Gasser, G. Beaudoin-Bussieres, N. Brassard, A. Laumaea, D. Vezina, J. Prevost, S. P. Anand, C. Bourassa, G. Gendron-Lepage, H. Medjahed, G. Goyette, , A. Finzi

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

bioRxiv · Mar 18, 2021 · PreprintImmunology

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

S. P. Anand, J. Prevost, M. Nayrac, G. Beaudoin-Bussieres, M. Benlarbi, R. Gasser, N. Brassard, A. Laumaea, S. Y. Gong, C. Bourassa, E. Brunet-Ratnasingham, H. Medjahed, G. Gendron-Lepage, G. Goyette, L. Gokool, , A. Finzi

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

bioRxiv · Jan 25, 2021Microbiology

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

R. Gasser, M. Cloutier, J. Prevost, C. Fink, E. Ducas, S. Ding, N. Dussault, P. Landry, T. Tremblay, A. Laforce-Lavoie, A. Lewin, G. Beaudoin-Bussieres, A. Laumaea, H. Medjahed, C. Larochelle, , A. Finzi

This study shows that IgM plays a major role in neutralizing SARS-CoV-2 in convalescent plasma, with its depletion causing the greatest loss of neutralizing activity.

bioRxiv · Oct 9, 2020Microbiology

Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles

M. Lu, P. D. Uchil, W. Li, D. Zheng, D. S. Terry, J. Gorman, W. Shi, B. Zhang, T. Zhou, S. Ding, R. Gasser, J. Prevost, G. Beaudoin-Bussieres, S. P. Anand, A. Laumaea, , W. Mothes

This study uses smFRET to observe real-time conformational dynamics of SARS-CoV-2 spikes on virus particles, revealing multiple states and mechanisms of neutralization by antibodies and convalescent plasma.

bioRxiv · Sep 10, 2020Microbiology

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins

S. P. Anand, Y. Chen, J. Prevost, R. Gasser, G. Beaudoin-Bussieres, C. F. Abrams, M. Pazgier, A. Finzi

This study compares the cooperativity of ACE2 binding to SARS-CoV-1 and SARS-CoV-2 Spike proteins, finding that SARS-CoV-2 exhibits positive cooperativity.

bioRxiv · Sep 7, 2020Microbiology

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

J. Perreault, T. Tremblay, M.-J. Fournier, M. Drouin, G. Beaudoin-Bussieres, J. Prevost, A. Lewin, P. Begin, A. Finzi, R. Bazin

The paper tracks antibody levels against SARS-CoV-2 RBD in convalescent plasma donors over time, finding a decline in antibodies after ~76 days post-symptoms onset.

bioRxiv · Jul 16, 2020 · PreprintImmunology

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

J. Prevost, R. Gasser, G. Beaudoin-Bussieres, J. Richard, R. Duerr, A. Laumaea, S. P. Anand, G. Goyette, M. Benlarbi, S. Ding, H. Medjahed, A. Lewin, J. Perreault, T. Tremblay, G. Gendron-Lepage, , A. Finzi

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.

bioRxiv · Jun 8, 2020Microbiology